DonaldPLawrenceMD

Oncology • Boston, MA

Hematologic Oncology

Physician

Join to view full profile

Dr. Lawrence is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lawrence's full profile

Already have an account?

Office
55 Fruit Street Yaw 9
Hematology Oncology
Boston, MA 02114
Phone+1 617-724-4000
Is this information wrong?

Education & Training

Tufts Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1991 - 1994
Albert Einstein College of MedicineClass of 1991

Certifications & Licensure

MA State Medical License 1993 - 2024

Clinical Trials

Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
Withdrawn
Not Applicable
Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2009 Jul 02
Completed
Phase 2
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma Start of enrollment: 2009 Jan 23
Completed
Phase 2
Selumetinib in Cancers With BRAF Mutations Start of enrollment: 2009 Jul 01
Completed
Phase 2
STA-9090(Ganetespib) in Metastatic Ocular Melanoma Start of enrollment: 2010 Sep 17
Completed
Phase 2
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma Start of enrollment: 2011 Nov 01
Completed
Phase 2
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Start of enrollment: 2013 Aug 01
Terminated
Phase 2
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) Start of enrollment: 2019 Aug 20
Recruiting
Phase 1
Roles: Contact, Principal Investigator
ITIL-168 in Advanced Melanoma Start of enrollment: 2021 Oct 07
Terminated
Phase 2
Roles: Principal Investigator
A Study to Investigate LYL845 in Adults With Solid Tumors Start of enrollment: 2022 Dec 19
Recruiting
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy.
Or-Yam Revach, Angelina M Cicerchia, Ofir Shorer, Boryana Petrova, Seth Anderson, Joshua Park, Lee Chen, Arnav Mehta, Samuel J Wright, Niamh McNamee, Aya Tal-Mason, Gi...> ;Biorxiv. 2024 Mar 26
5 citations
Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results.
Priscilla K Brastianos, Albert E Kim, Anita Giobbie-Hurder, Eudocia Q Lee, Nancy U Lin, Beth Overmoyer, Patrick Y Wen, Lakshmi Nayak, Justine V Cohen, Jorg Dietrich, A...> ;Nature Medicine. 2023 Jul 1
2 citations
Dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF-mutant solid tumors.
Meghan J Mooradian, James M Cleary, Anita Giobbie-Hurder, Lancia N F Darville, Aparna Parikh, Elizabeth I Buchbinder, Justine V Cohen, Donald P Lawrence, Geoffrey I Sh...> ;Cancer. 2023 Jun 15
1 citations
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Suzanne L Topalian, Mario Sznol, David F McDermott, Harriet M Kluger, Richard D Carvajal, William H Sharfman, Julie R Brahmer, Donald P Lawrence, Michael B Atkins, Joh...> ;Journal of Clinical Oncology. 2023 Feb 10
7 citations
Identification of fusions with potential clinical significance in melanoma.
Jakob M T Moran, Long P Le, Valentina Nardi, Josephine Golas, Alexander A Farahani, Sylvia Signorelli, Maristela L Onozato, Ruth K Foreman, Lyn M Duncan, Donald P Lawr...> ;Modern Pathology. 2022 Dec 1
20 citations
Benefit and toxicity of programmed death-1 blockade vary by ethnicity in patients with advanced melanoma: an international multicentre observational study.
Xue Bai, Alexander N Shoushtari, Allison Betof Warner, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Henry T Quach, Christopher G Cann, Michael Z Zha...> ;The British Journal of Dermatology. 2022 Sep 1
3 citations
Association between serum lactate dehydrogenase and cutaneous immune-related adverse events among patients on immune checkpoint inhibitors for advanced melanoma.
Maria S Asdourian, Tracey S Otto, Ted V Jacoby, Leah L Thompson, Steven M Blum, Kerry L Reynolds, Yevgeniy R Semenov, Donald P Lawrence, Ryan J Sullivan, Genevieve M B...> ;Journal of the American Academy of Dermatology. 2022 Nov 1
13 citations
Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma.
Samuel S Freeman, Moshe Sade-Feldman, Jaegil Kim, Chip Stewart, Anna L K Gonye, Arvind Ravi, Monica B Arniella, Irena Gushterova, Thomas J LaSalle, Emily M Blaum, Kere...> ;Cell Reports. Medicine. 2022 Feb 15
8 citations
Combining CTLA-4 and angiopoietin-2 blockade in patients with advanced melanoma: a phase I trial.
Patrick A. Ott, Matthew Nazzaro, Kathleen L. Pfaff, Evisa Gjini, Kristen Felt, Jacquelyn O. Wolff, Elizabeth I. Buchbinder, Rizwan Haq, Ryan J. Sullivan, Donald P. Law...> ;Journal for Immunotherapy of Cancer. 2021 Nov 1
4 citations
Long-term Overall Survival and Predictors in Anti-PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Settin...
Girish S. Naik, Elizabeth I. Buchbinder, Justine V. Cohen, Michael Manos, Alistair E. W. Johnson, Peter Bowling, Ayal A. Aizer, Jonathan D. Schoenfeld, Donald P. Lawre...> ;Journal of Immunotherapy. 2021 Aug 18
Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael D. Gordon, Leonel Hernandez-Aya, Donald P. Lawrence, Jose Lutzky, Wilson H....> ;Nature Communications. 2021 Aug 12
53 citations
Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.
Xue Bai, Jiani Hu, Allison Betof Warner, Henry T. Quach, Christopher G. Cann, Michael Z. Zhang, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Lalit P...> ;Clinical Cancer Research. 2021 Aug 10
1 citations
Immune Checkpoint Inhibition in Marjolin Ulcer: A Case Series.
Sophia Z Shalhout, Howard L. Kaufman, Ryan J. Sullivan, Donald P. Lawrence, David Miller> ;Journal of Immunotherapy. 2021 Jul 1
5 citations
Rejection of benign melanocytic nevi by nevus-resident CD4+ T cells.
Erik Schiferle, Se Yun Cheon, Seokjin Ham, Heehwa G. Son, Jonathan L. Messerschmidt, Donald P. Lawrence, Justine V. Cohen, Keith T. Flaherty, James J. Moon, Christine ...> ;Science Advances. 2021 Jun 1
56 citations
Evolution of delayed resistance to immunotherapy in a melanoma responder
David Liu, Jia-Ren Lin, Emily J. Robitschek, Gyulnara G. Kasumova, Alexander Heyde, Alvin Shi, Adam A. Kraya, Gao Zhang, Tabea Moll, Dennie T. Frederick, Yu-An Chen, S...> ;Nature Medicine. 2021 May 3
23 citations
Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations
Priscilla K. Brastianos, Albert E. Kim, Nancy Wang, Eudocia Q. Lee, Jennifer A. Ligibel, Justine V. Cohen, Ugonma Chukwueke, Maura Mahar, Kevin S. Oh, Michael White, H...> ;Nature Cancer. 2021 May 1
10 citations
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.
Ahmad A. Tarhini, Ni Kang, Sandra J. Lee, F. Stephen Hodi, Gary I. Cohen, Omid Hamid, Laura F. Hutchins, Jeffrey A. Sosman, Harriet M. Kluger, Zeynep Eroglu, Henry B. ...> ;Journal for Immunotherapy of Cancer. 2021 May 1
7 citations
Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an intern...
Xue Bai, Michelle Kim, Gyulnara G. Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Justine V. Cohen, Donald P. Lawrence, Christine Freedman, ...> ;Journal for Immunotherapy of Cancer. 2021 Feb 1
17 citations
Clinical Outcomes of Patients with Metastatic Cancer Receiving Immune Checkpoint Inhibitors in the Inpatient Setting
Sienna Durbin, Leyre Zubiri, Andrzej Niemierko, Aditya Bardia, Ryan J. Sullivan, Corey L. McEwen, Therese M. Mulvey, Ian M. Allen, Donald P. Lawrence, Justine V. Cohen...> ;The Oncologist. 2021 Jan 1
2 citations
Dual hereditary and immune‐mediated neuromuscular diagnoses after cancer immunotherapy
Nadim S Jiwa, Donald P. Lawrence, Amanda C. Guidon> ;Muscle & Nerve. 2021 Mar 1
42 citations
PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
Antoni Ribas, Alain Algazi, Paolo A. Ascierto, Marcus O. Butler, Sunandana Chandra, Michael D. Gordon, Leonel Hernandez-Aya, Donald P. Lawrence, Jose Lutzky, Wilson H....> ;Nature Communications. 2020 Dec 7
4 citations
Publisher Correction: Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.
Priscilla K. Brastianos, Eudocia Q. Lee, Justine V. Cohen, Sara M. Tolaney, Nan Lin, Nancy Wang, Ugonma Chukwueke, Michael White, Naema Nayyar, Albert H. Kim, Christop...> ;Nature Medicine. 2020 Aug 1
70 citations
Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis
Priscilla K. Brastianos, Eudocia Q. Lee, Justine V. Cohen, Sara M. Tolaney, Nan Lin, Nancy Wang, Ugonma Chukwueke, Michael White, Naema Nayyar, Albert H. Kim, Christop...> ;Nature Medicine. 2020 Aug 1
3 citations
Central Nervous System–Invading Eccrine Gland Carcinoma: A Clinicopathologic Case Series and Literature Review
Saksham Gupta, Alexander F. C. Hulsbergen, David J Segar, Blake M. Hauser, Joshua D. Bernstock, Rosalynn M. Nazarian, Donald P. Lawrence, Brian V. Nahed, Marike L. D. ...> ;World Neurosurgery. 2020 Mar 3
180 citations
Cardiovascular magnetic resonance in immune checkpoint inhibitor-Associated myocarditis
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;European Heart Journal. 2020 May 7
Join now to see all